[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Bispecific Antibodies for Cancer Market Size, Trends, Analysis, and Outlook By Type (CD19 or CD3, CD30 or CD16A), By Distribution Channel (Hospitals, Retail pharmacies, Online), by Region, Country, Segment, and Companies, 2024-2030

March 2024 | 190 pages | ID: B3BA88B1B191EN
VPAResearch

US$ 3,980.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Bispecific Antibodies for Cancer market size is poised to register 9.28% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Bispecific Antibodies for Cancer market By Type (CD19 or CD3, CD30 or CD16A), By Distribution Channel (Hospitals, Retail pharmacies, Online).

The future of cancer treatment is shaped by the development of bispecific antibodies that target multiple cancer pathways simultaneously, offering enhanced efficacy and reduced treatment resistance. Bispecific antibodies designed to engage immune effector cells, such as T cells and natural killer cells, with tumor-specific antigens promote targeted cell killing and immune-mediated tumor clearance. Moreover, the incorporation of tumor-targeting domains and immune checkpoint inhibitors into bispecific antibody constructs enhances tumor specificity and immune activation, overcoming immune evasion mechanisms employed by cancer cells. Additionally, the advent of bispecific antibody-drug conjugates and combination therapies with standard-of-care treatments offers synergistic anticancer effects and improves patient outcomes across various cancer types..

Bispecific Antibodies for Cancer Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Bispecific Antibodies for Cancer market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Bispecific Antibodies for Cancer survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Bispecific Antibodies for Cancer industry.

Key market trends defining the global Bispecific Antibodies for Cancer demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Bispecific Antibodies for Cancer Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Bispecific Antibodies for Cancer industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Bispecific Antibodies for Cancer companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Bispecific Antibodies for Cancer industry

Leading Bispecific Antibodies for Cancer companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Bispecific Antibodies for Cancer companies.

Bispecific Antibodies for Cancer Market Study- Strategic Analysis Review

The Bispecific Antibodies for Cancer market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
  • Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
  • Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
  • Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
  • Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
Bispecific Antibodies for Cancer Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Bispecific Antibodies for Cancer industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Bispecific Antibodies for Cancer Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Bispecific Antibodies for Cancer Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Bispecific Antibodies for Cancer market segments. Similarly, Strong end-user demand is encouraging Canadian Bispecific Antibodies for Cancer companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Bispecific Antibodies for Cancer market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Bispecific Antibodies for Cancer Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Bispecific Antibodies for Cancer industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Bispecific Antibodies for Cancer market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Bispecific Antibodies for Cancer Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Bispecific Antibodies for Cancer in Asia Pacific. In particular, China, India, and South East Asian Bispecific Antibodies for Cancer markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Bispecific Antibodies for Cancer Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Bispecific Antibodies for Cancer Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Bispecific Antibodies for Cancer market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Bispecific Antibodies for Cancer.

Bispecific Antibodies for Cancer Market Company Profiles

The global Bispecific Antibodies for Cancer market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Aptevo Therapeutics Inc, Astellas Pharma Inc, Chugai Pharmaceutical Co. Ltd, Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS Inc, F STAR THERAPEUTICS Inc, F. Hoffmann-La Roche Ltd, Johnson and Johnson, Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc, Regeneron Pharmaceuticals Inc, TG Therapeutics Inc, Xencor Inc, YmAbs Therapeutics Inc.

Recent Bispecific Antibodies for Cancer Market Developments

The global Bispecific Antibodies for Cancer market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Bispecific Antibodies for Cancer Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis
  • Pricing Analysis
  • Value Chain Analysis
  • SWOT Profile
  • Market Dynamics- Trends, Drivers, Challenges
  • Porter’s Five Forces Analysis
  • Macroeconomic Impact Analysis
  • Case Scenarios- Low, Base, High
Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:
  • North America (3 markets)
  • Europe (6 markets)
  • Asia Pacific (6 markets)
  • Latin America (3 markets)
  • Middle East Africa (5 markets)
Companies

Aptevo Therapeutics Inc

Astellas Pharma Inc

Chugai Pharmaceutical Co. Ltd

Eli Lilly and Co.

EPIMAB BIOTHERAPEUTICS Inc

F STAR THERAPEUTICS Inc

F. Hoffmann-La Roche Ltd

Johnson and Johnson

Mereo BioPharma Group Plc

Merus N.V.

Pfizer Inc

Regeneron Pharmaceuticals Inc

TG Therapeutics Inc

Xencor Inc

YmAbs Therapeutics Inc

Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY

1.1 Bispecific Antibodies for Cancer Market Overview and Key Findings, 2024
1.2 Bispecific Antibodies for Cancer Market Size and Growth Outlook, 2021- 2030
1.3 Bispecific Antibodies for Cancer Market Growth Opportunities to 2030
1.4 Key Bispecific Antibodies for Cancer Market Trends and Challenges
  1.4.1 Bispecific Antibodies for Cancer Market Drivers and Trends
  1.4.2 Bispecific Antibodies for Cancer Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Bispecific Antibodies for Cancer Companies

2. BISPECIFIC ANTIBODIES FOR CANCER MARKET SIZE OUTLOOK TO 2030

2.1 Bispecific Antibodies for Cancer Market Size Outlook, USD Million, 2021- 2030
2.2 Bispecific Antibodies for Cancer Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024

3. BISPECIFIC ANTIBODIES FOR CANCER MARKET- STRATEGIC ANALYSIS REVIEW

3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis

4. BISPECIFIC ANTIBODIES FOR CANCER MARKET SEGMENTATION ANALYSIS AND OUTLOOK

4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Bispecific Antibodies for Cancer Market, 2025
5.2 Asia Pacific Bispecific Antibodies for Cancer Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Bispecific Antibodies for Cancer Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Bispecific Antibodies for Cancer Market, 2025
5.5 Europe Bispecific Antibodies for Cancer Market Size Outlook by Type, 2021- 2030
5.6 Europe Bispecific Antibodies for Cancer Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Bispecific Antibodies for Cancer Market, 2025
5.8 North America Bispecific Antibodies for Cancer Market Size Outlook by Type, 2021- 2030
5.9 North America Bispecific Antibodies for Cancer Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Bispecific Antibodies for Cancer Market, 2025
5.11 South America Pacific Bispecific Antibodies for Cancer Market Size Outlook by Type, 2021- 2030
5.12 South America Bispecific Antibodies for Cancer Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Bispecific Antibodies for Cancer Market, 2025
5.14 Middle East Africa Bispecific Antibodies for Cancer Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Bispecific Antibodies for Cancer Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

6.1 US Bispecific Antibodies for Cancer Market Size Outlook and Revenue Growth Forecasts
6.2 US Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Bispecific Antibodies for Cancer Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Bispecific Antibodies for Cancer Industry Drivers and Opportunities

7. BISPECIFIC ANTIBODIES FOR CANCER MARKET OUTLOOK ACROSS SCENARIOS

7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case

8. BISPECIFIC ANTIBODIES FOR CANCER COMPANY PROFILES

8.1 Profiles of Leading Bispecific Antibodies for Cancer Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Aptevo Therapeutics Inc
Astellas Pharma Inc
Chugai Pharmaceutical Co. Ltd
Eli Lilly and Co.
EPIMAB BIOTHERAPEUTICS Inc
F STAR THERAPEUTICS Inc
F. Hoffmann-La Roche Ltd
Johnson and Johnson
Mereo BioPharma Group Plc
Merus N.V.
Pfizer Inc
Regeneron Pharmaceuticals Inc
TG Therapeutics Inc
Xencor Inc
YmAbs Therapeutics Inc

9. APPENDIX

9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information


More Publications